Clovis Oncology Announces First Patient Enrolled in ARIEL2 Study of Rucaparib in Ovarian Cancer
Published: Oct 31, 2013
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the global ARIEL2 (Assessment of Rucaparib in Ovarian Cancer Phase 2 Trial) study of rucaparib has commenced with the dosing of the first patient at a U.S. study site. Rucaparib is the Company’s oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of platinum sensitive, relapsed ovarian cancer.
Help employers find you! Check out all the jobs and post your resume.